KBLB Kraig Biocraft Laboratories, Inc.
Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) · OTC · SEC CIK 1413119 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-5.3%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-127.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets300.7%
Debt / equity—
Current ratio0.27x
Interest coverage-5.67x
Cash quality & payout
Operating cash flow / net income0.56x
Accruals ratio-56.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $165,758 | $164,374 | $237,871 | $176,431 | $197,745 |
| SG&A expense | $1.96M | $1.75M | $1.45M | $825,460 | $1.50M |
| Operating income | -$3.37M | -$3.07M | -$2.61M | -$2.12M | -$2.76M |
| Interest expense | $570,709 | $529,603 | $484,658 | $153,955 | $238,110 |
| Pretax income | -$3.62M | -$3.40M | -$3.03M | -$3.84M | -$8.05M |
| Net income | -$3.62M | -$3.40M | -$3.03M | -$3.84M | -$8.05M |
| EBITDA | -$3.35M | -$3.05M | -$2.59M | -$2.09M | -$2.73M |
| EPS (basic) | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Weighted avg. shares (diluted) | 1.06B | 1.04B | 1.03B | 974.31M | 877.61M |
| Balance sheet | |||||
| Cash & equivalents | $1.79M | $673,264 | $2.55M | $3.86M | $2.36M |
| Short-term investments | $0 | $0 | $0 | — | — |
| Inventory | $29,067 | $6,884 | $6,884 | $6,580 | — |
| Current assets | $1.87M | $740,285 | $2.57M | $3.98M | $2.37M |
| PP&E, net | $25,003 | $44,721 | $66,640 | $87,861 | $110,943 |
| Total assets | $2.57M | $1.51M | $3.23M | $4.57M | $3.02M |
| Current liabilities | $10.45M | $9.61M | $8.89M | $8.07M | $8.16M |
| Total liabilities | $10.56M | $9.65M | $8.94M | $8.09M | $8.32M |
| Shareholders' equity | -$8.00M | -$8.15M | -$5.71M | -$3.52M | -$5.30M |
| Cash flow statement | |||||
| Operating cash flow | -$1.79M | -$1.84M | -$1.24M | -$1.89M | -$1.80M |
| Capital expenditure | $5,395 | $4,240 | $6,399 | $5,021 | $97,154 |
| Free cash flow | -$1.79M | -$1.84M | -$1.25M | -$1.89M | -$1.90M |
| Investing cash flow | $438,042 | -$4,240 | -$6,399 | -$5,021 | -$547,370 |
| Financing cash flow | $2.47M | -$35,244 | -$60,000 | $3.40M | $3.89M |
| Depreciation & amortization | $25,113 | $26,159 | $27,620 | $28,103 | $26,137 |
| Stock-based compensation | $87,285 | — | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.